BioAge Labs
Richmond
About BioAge Labs
BIOAGE discovers and develops drugs to treat aging and associated diseases. The company's primary initiative, azelaprag, is an oral APJ agonist on track for Phase 2 trials in conjunction with tirzepatide to potentially become a groundbreaking treatment for obesity in the elderly.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Total funding: $408.9M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:BIOA
- Website: bioagelabs.com
- Phone: [email protected]
Industries & Categories
Biopharma, Biotechnology, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/bioage-labs-2901 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.